Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00178243|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : September 8, 2006
A study is being conducted by the University of Rochester Cancer Center (URCC) in which patients with liver cancer will be treated with high dose conformal radiation therapy. This type of radiation uses new techniques which aim the radiation to the sites of disease allowing the tumor to receive a high dose and the surrounding normal liver tissue to receive a low enough dose that the normal tissue should remain free from injury.
The purpose of the study is to determine if the conformal radiation therapy is safe, tolerable and effective in treating liver cancer and to determine the side effects caused by this treatment. A second objective is to determine if the levels of a special type of protein (called cytokines) found in the blood are related to this treatment.
|Condition or disease||Intervention/treatment||Phase|
|Liver Neoplasms Neoplasm Metastasis||Procedure: 3D Conformal Radiation Therapy and Radiosurgery||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Trial Of the Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation Delivered by 3D Conformal Radiation Therapy and Radiosurgery|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00178243
|United States, New York|
|University of Rochester, Dept. Radiation Oncology|
|Rochester, New York, United States, 14642|
|Principal Investigator:||Paul Okunieff, MD||Universtiy of Rochester, Dept of Radiation Oncology|